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Abstract
Objectives: Resource allocation is a challenging issue faced by health policy decisionmakers requiring careful
consideration of many factors. Objectives of this study were to identify decision criteria and their frequency
reported in the literature on healthcare decisionmaking.
Method: An extensive literature search was performed in Medline and EMBASE to identify articles reporting
healthcare decision criteria. Studies conducted with decisionmakers (e.g., focus groups, surveys, interviews),
conceptual and review articles and articles describing multicriteria tools were included. Criteria were extracted,
organized using a classification system derived from the EVIDEM framework and applying multicriteria decision
analysis (MCDA) principles, and the frequency of their occurrence was measured.
Results: Out of 3146 records identified, 2790 were excluded. Out of 356 articles assessed for eligibility, 40 studies
included. Criteria were identified from studies performed in several regions of the world involving decisionmakers
at micro, meso and macro levels of decision and from studies reporting on multicriteria tools. Large variations in
terminology used to define criteria were observed and 360 different terms were identified. These were assigned to
58 criteria which were classified in 9 different categories including: health outcomes; types of benefit; disease
impact; therapeutic context; economic impact; quality of evidence; implementation complexity; priority, fairness and
ethics; and overall context. The most frequently mentioned criteria were: equity/fairness (32 times), efficacy/
effectiveness (29), stakeholder interests and pressures (28), cost-effectiveness (23), strength of evidence (20), safety
(19), mission and mandate of health system (19), organizational requirements and capacity (17),
patient-reported outcomes (17) and need (16).
Conclusion: This study highlights the importance of considering both normative and feasibility criteria for fair
allocation of resources and optimized decisionmaking for coverage and use of healthcare interventions. This
analysis provides a foundation to develop a questionnaire for an international survey of decisionmakers on criteria
and their relative importance. The ultimate objective is to develop sound multicriteria approaches to enlighten
healthcare decisionmaking and priority-setting.
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Introduction
Resource allocation and priority setting are challenging
issues faced by health policy decisionmakers requiring
careful consideration of many factors, including object-
ive (e.g., reason) and subjective (e.g., empathy) elements
[1]. Criteria used to evaluate healthcare interventions
and allocate resources are likely to have profound impli-
cations, especially regarding ethical aspects. Ethical prin-
ciples of resource allocation set forth by the World
Health Organization (WHO) include efficiency (maxi-
mizing population health), fairness (minimizing health
differences) and utility (greatest good for the greatest
number) [2]. Consideration of these often conflicting
principles requires pragmatic frameworks and the en-
gagement of a broad range of stakeholders to provide ac-
countability for reasonableness (A4R) [3-7]. Limited
resources and inequities in healthcare in both wealthy
and developing countries underline the need to allocate
optimally [8].
As argued by various authors [9-12], choices may not
be based on rational and transparent processes high-
lighting the need for processes that take this into ac-
count. Indeed, if the mechanism employed to guide the
distribution of resources is inequitable, the outcome is
also likely to be. Thus, how resources are allocated by
health policy decisionmakers around the world remains
a challenging issue [13]. Priority-setting is defined as the
process by which healthcare resources are allocated
among competing programs or people [14]. In the con-
text of increasing healthcare costs in many countries
around the world, effective approaches to explicit ap-
praisal and priority setting are becoming critical to allo-
cate resources to healthcare interventions that provide
the most benefit to patient health as well as contributing
to healthcare systems’ sustainability, equity and effi-
ciency. Indeed, elucidating decision criteria and how
they are considered are key to establishing accountability
and reasonableness of decisions and fulfils the A4R
framework set forth by Daniels and Sabin [6].
Over the past decades, a number of empirical studies
have explored systematic approaches to optimize evalu-
ation of healthcare interventions and priority-setting. A
number of tools with defined criteria to evaluate and
rank interventions have been developed, recognizing
the need for such approaches [10,15-28]. As part of a
larger collaborative endeavour exploring decision
criteria, the aim of this study was to analyse the peer-
reviewed literature to identify criteria reported in em-
pirical studies that involved healthcare decisionmakers
and in studies describing multicriteria tools. The spe-
cific objectives were to identify, categorize and esti-
mate the frequency of decision criteria reported in the
literature. This work will support the design of an
international survey of decisionmakers on criteria and
their relative importance as well as providing a resource
for developers of multicriteria-based frameworks.
Methods
Search strategy and article selection
An extensive literature search was carried out in June
2010 on Medline and EMBASE databases to identify
articles reporting healthcare decision criteria. Because
studies reporting criteria (or factors or principles or
components) are usually not indexed with such generic
terms and because these terms are used in many fields
(e.g., diagnostic criteria), a number of algorithms were
explored to optimize the search strategy. The optimized
search strategy included the following keywords:
“decision-making”, “priority-setting”, and “resource alloca-
tion”, combined with “funding”, “budget”, “cost-benefit
analysis”, “cost-effectiveness analysis”, and “equity”. The
research was limited to articles published in English,
French, or German over the last 10 years and excluded
the following types of studies: clinical trials (phase I to
IV), editorials, letters, randomized controlled trials, case
reports, and comparative studies. Bibliographies of rele-
vant articles were also searched.
Abstracts of articles thus retrieved were screened to
identify appropriate inclusion and exclusion criteria.
Studies were included if they reported a set (i.e., > 1) of
decision criteria and were:
 empirical studies conducted with healthcare
decisionmakers (including field-testing of
decisionmaking tools, focus groups, questionnaires,
interviews)
 reviews of such empirical studies, and
 conceptual studies describing or proposing a set of
decision criteria or a decisionmaking tool.
Studies were excluded if they focused on a single cri-
terion (e.g., cost-effectiveness only) or described a
priority-setting exercise without explicitly identifying de-
cision criteria. Studies discussing the goals and advan-
tages of priority-setting per se without reporting specific
criteria were also excluded. To avoid double-counting of
decision criteria, only one publication was included if
several publications from the same group described the
same set of decision criteria. For the same reason, stud-
ies reported in review articles that we included in our
analysis and which reported the criteria of the original
studies were also excluded.
Data extraction
Full texts of selected articles were reviewed and data
extracted into a table identifying: 1) first author; 2)
year of publication 3) method of criteria elicitation or
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identification, 4) decisionmaking setting, 5) exact term
for each criterion as reported in the publication.
Given the variability of terms to describe conceptually
similar decision criteria, a hierarchical classification sys-
tem was developed (Figure 1). Terms referring to the
same concept (e.g., “side-effects” and “harm”) were
grouped under one criterion (e.g., Safety). Related cri-
teria were grouped under categories (e.g., Health out-
comes and benefits of intervention). This process of
classification was guided by the structure of the EVI-
DEM framework, which includes an adaptable set of
core and contextual criteria identified from analyses of
the literature, of decisionmaking processes worldwide,
and discussions with decisionmakers, and which were
structured to fulfill the requirements of multicriteria de-
cision analysis (MCDA; i.e., minimum overlap, mutual
independence, operationalizability, completeness and
clustering) [10,18,29]. MCDA principles were applied in
the present study to define criteria regrouping terms re-
ferring to the same concept and to categorize criteria
into a meaningful and intuitive architecture (clustering).
Descriptive statistics
The number of times each criterion was cited in the
studies retrieved was used as a proxy to identify the cri-
teria perceived to be most important. Descriptive statis-
tics were performed and each occurrence of a term
belonging to that criterion was counted. If a study
reported two different terms that we grouped under the
same criterion, both terms were counted. For example, if
a study reported “side effects” and “harm” as separate
terms, we counted both of them under the criterion
“Safety”. The numbers of citations for each criterion and
for each category of criteria were analyzed.
Results
Identification of decision criteria from the literature review
The literature search resulted in a total of 2903 records
identified through PUBMED and EMBASE database
searching and 243 additional records were identified
through bibliographic hand searching (Figure 2). These
studies were screened by their abstracts and 2790 were
excluded. The remaining 364 studies were assessed for
eligibility on the basis of full text and 317 articles were
excluded. A total of 40 studies were included (Table 1),
all of which were published after 1997, and 33 studies
from 2006 to 2010. The majority of studies reported cri-
teria derived from interviews and focus groups (9 studies
each) surveys (2) or literature review of studies (5) con-
ducted with healthcare decisionmakers at micro, meso
and macro levels of decision and from several regions of
the world. Fourteen studies described multicriteria deci-
sionmaking tools.
Decision criteria classification and descriptive statistics
Large variations in terminology used to define criteria
were observed among the studies included; 360 different
terms were identified (Table 2). Using the classification
system described above, these terms were assigned to 58
unique criteria which were classified into 9 different cat-
egories. These were: A) health outcomes and benefits of
intervention (6 criteria), B) types of health benefit (2 cri-
teria), C) impact of disease targeted by intervention (4
criteria), D) therapeutic context of intervention (4 cri-
teria), E) economic impact of intervention (9 criteria), F)
quality/uncertainty of evidence (6 criteria), G) imple-
mentation complexity of intervention (9 criteria), H) pri-
orities, fairness and ethics (7 criteria), I) overall context
(11 criteria). Categories were defined to: i) regroup cri-
teria pertaining to the same overall concept (e.g., cat-
egory “A - Health outcomes and benefits” of intervention
includes criteria such as health benefits, life saving, effi-
cacy, effectiveness, safety, patient-reported outcomes and
quality of care) and to ii) disentangle criteria specific to
the intervention (categories A to F) from criteria specific
to the context (G to I).
The classification system and the number of citations
for each criterion are reported in Figure 3. The ten most
Side-effect Harm Adverse 
effects
Etc
A - Health outcomes 
and benefits of 
intervention
A4 - Safety EtcA1- Health 
benefits
Terms 
(reported 
in articles)
Criteria 
(classification 
System)
Categories
(classification 
System)
Figure 1 Categorization of terms reported in the literature.
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frequently mentioned criteria were: equity, fairness and
justice (H4, 32 citations); efficacy/effectiveness (A2, 29
citations); stakeholder interests and pressures (I11, 28
citations); cost-effectiveness (E5, 23 citations); strength
of evidence (F2, 20 citations); safety (A4, 19 citations);
mission and mandate of health system (I1:19 citations);
organizational requirements and capacity (G2, 17 cita-
tions); patient-reported outcomes (A5, 17 citations); and
Records identified through database searching  
(n= 2903)
Additional records identified through other sources 
(n= 243)
Records after duplicates removed (n=3146 )
Records retained after screening 
by abstract (n=1500 )
Records excluded 
(n=1646)*
Full-text articles assessed for 
eligibility (n= 364) Full-text articles excluded (n= 1136)*
Studies included in the literature 
review (n=40 )
Figure 2 PRISMA diagram.
Table 1 Studies identified in the literature and included in the analysis
Studies reporting on decision criteria Studies describing a decisionmaking tool
Authors Type of study and level of decisionmaking*
1. Andreae et al. [9], 2009 Survey, macro 1. Bowen et al. [15], 2005
2. Asante et al. [8], 2009 Interviews, meso & macro 2. Browman et al. [16], 2008
3. Baltussen et al. [12], 2007 Focus group, macro 3. Ghaffar et al. [17], 2010
4. Baltussen et al. [30], 2006 Focus group, meso & macro 4. Goetghebeur et al. [10,18], 2008,2010
5. Baltussen et al. [11], 2006 Methodology 5. Golan et al. [19], 2010
6. Dionne et al. [31], 2009 Interviews, macro 6. Hailey et al. [20], 2009
7. Dolan et al. [32], 2010 Methodology 7. Honore et al. [21], 2010
8. Duthie et al. [33], 1997 Interviews, micro, meso & macro 8. Johnson et al. [22], 2009
9. Gibson et al. [34], 2006 Focus group & interviews, meso & macro 9. Kirby et al. [23], 2008
10. Hofmann et al. [35], 2005 Literature review 10. Meagher et al. [24], 2010
11. Irving et al. [36], 2010 Interviews, micro 11. Menon et al. [25], 2010
12. Jehu-Appiah et al. [37], 2008 Focus group, macro 12. Tannahill et al. [26], 2008
13. Kapiriri et al. [38], 2009 Interviews, micro, meso & macro 13. The University of York [27], 2002
14. Koopmanschap et al. [39], 2010 Focus group, macro 14. Wilson et al. [28], 2006
15. Lasry et al. [14], 2010 Interviews, macro
16. Lehoux et al. [40], 2007 Literature review
17. Lopert et al. [41], 2009 Focus group, macro
18. Martin et al. [42], 2001 Focus group, macro
19. Mitton et al. [43], 2006 Focus group, macro
20. Mullen et al. [44], 2004 Survey, meso
21. Noorani et al. [45], 2007 Literature review and interviews, macro
22. Saarni et al. [46], 2008 Consensus procedure, macro
23. Vuorenkoski et al. [47], 2008 Literature review
24. Wilson et al. [48], 2007 Focus group, macro
25. Wirtz et al. [49], 2005 Interviews, macro
26. Youngkong et al. [13], 2009 Literature review
*Survey, interviews and focus groups were performed with healthcare decisionmakers making decisions at national or regional level (macro level), at a healthcare
facility level (meso level) and/or at the healthcare provider level (micro level).
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Table 2 Classification of terms reported in the literature
Categories of classification
system
Criteria of classification
system
Terms used in articles
A-Health outcomes and
benefits of intervention
Number of criteria: 6 Number of terms: 44
A1: Health benefits:
7 terms, cited 10 times
 A1 – health benefits[13,31,38,50], potential health gain[44],
enhanced health outcomes[44], relative advantage[51], health
effects[30], additional effects[22], incremental health gain[43]
A2: Efficacy/effectiveness:
11 terms, cited 29 times
 A2 – efficacy[13,47], efficacy/effectiveness[10,19,20,25,27,28,44,48],
effectiveness[14,22,26,32-34,48], clinical benefit[19,22,24,42,47],
clinical impact[45], clinical merit[22], relative clinical benefit in relation
with current standards[16], determine relative value for degree of
benefit against benchmarks[16], magnitude of treatment effect[22],
response rate[43], onset and duration of treatment/program effect[43]
A3: Life saving:
4 terms, cited 5 times
 A3 – prolongation of disease-free survival[42], saving life[19],
life expectancy gains[13], average life-year benefit per patient[13,33]
A4: Safety: 11 terms,
19 times
 A4 – side effects[33,41,47], unintended consequences[40],
safety[9,22,26,31], safety and tolerability[10,19,20], risks[20,22], risk
management[44], harm[42], adverse effects[32], inconvenience[22], risk
of event[22], reduction in symptomatic toxicity compared with
standard therapy[42]
A5: PRO: 10 terms,
17 times
 A5 – patients reported outcomes[10], quality of life[19,42,44,52],
impact on quality of life[22,43], number of QALYs gained per
patient[36,39], disability adjusted life years[13], likely impact on
patient[16], patient preference[25], patient autonomy[26,35,40],
relative value to patient[16], best for patient[38]
A6: Quality of care: 1 term, 1 time  A6 – overall gain in quality of care[44]
B-Type of health benefit Number of criteria: 2 Number of terms: 12
B1: Population effect
(prevention): 6 terms,
11 times
 B1 – public health interest[10], population effects[19],
prevention[19,28], prevention of ill health[44], social impact[13,22,33],
social benefit[13,22,33]
B2: Individual effect
(medical service): 6 terms,
7 times
 B2 – type of medical service[10], relief/prevention of
symptoms/complications of disease[42], health gain or
maintenance[44], individual effects[19], individual impact and
benefit[13,33], the composition of the health gain[39]
C-Impact of the disease
targeted by
intervention
Number of criteria: 4 Number of terms: 21
C1: Disease severity:
2 terms, 9 times
 C1 – severity of disease[9,10,13,19,30,37,39,47], impact of the
disease/condition on quality of life[43]
C2: Disease determinants:
2 terms, 2 times
 C2 – determinants (the factors responsible for the persistence
of the burden)[17], characteristics of target condition[22]
C3: Disease burden:
7 terms, 13 times
 C3 – burden of disease[9,13,22,33], disease burden[17,25,45,48],
burden of illness[22], burden of therapy[22], cost to treat disease[33],
cost to prevent disease[33], national cost of the disease/condition
to the healthcare system[43]
C4: Epidemiology:
10 terms, 16 times
 C4 – prevalence[9,13], number of potential beneficiaries[35,37,40],
indirect beneficiaries[40], size of population[10,19], prevalence and
incidence of disease[23,25,43], number of residents benefiting[44],
number of clients served[43], number of patients[47],
social/demographics[22], incidence[22]
D-Therapeutic context
of intervention
Number of criteria: 4 Number of terms: 18
D1: Treatment alternatives:
5 terms, 13 times
 D1 – treatment alternatives[13,22], availability of
alternatives[16,19,25,42,44,47], availability of effective intervention and
preventable[13], alternatives[35,40,45], benchmark comparators[16]
D2: Need: 8 terms,
16 times
 D2 – comparative interventions limitations (unmet needs)[10],
need[19,22,28,38,42,44,49], clinical impact (need and trends)[24],
emergencies and need[13], apparent need[14], clinical
need[36,41,50], desirability of effects[40], meets patient’s basic need[38]
D3: Clinical guidelines &
practices: 4 terms, 7 times
 D3 – evidence-based guidelines[13,33,36], best practice[14],
clinical guidelines[10,23], academic health center research
(establishing/or using best practice)[24]
 D4 – pre-existing prescribing of the drug[47]
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Table 2 Classification of terms reported in the literature (Continued)
D4: Pre-existing use:
1 term, 1 time
E-Economic impact
of intervention
Number of criteria: 9 Number of terms: 36
E1: Cost: 3 terms,
11 times
 E1 – cost per patient[19], costs[19,20,22,27,32,42,44,47,51],
unit cost[22]
E2: Budget impact:
6 terms, 11 times
 E2 – budget impact on health plan[10,19,25,47], total
budget impact[30], budget impact[32,45,47], usage and cost
implications of competing new drugs if approved[16],
affordability[25], operating and start-up costs[43]
E3: Broad financial impact:
7 terms, 7 times
 E3 – impact on other spending[10], financial impact on
government[13], economic impact[45], economics[22], national
medical costs per-year[39], cost-saving[33], national saving in costs
of absence per year[39]
E4: Poverty reduction:
1 terms, 3 times
 E4 – positive poverty reduction[13,30,37]
E5: Cost-effectiveness:
5 terms, 23 times
 E5 – cost-effectiveness[9,10,13,14,17,20,22,25-27,30,34,37,39,41,44],
economic evaluations[27], cost and consequences[9,13,14,41],
pharmacoeconomic analysis[23], cost utility expressed as cost
per QALY[22]
E6: Value: 2 terms, 3 times  E6 – value for money[32,44], financial value[44]
E7: Efficiency and opportunity
costs: 6 terms, 10 times
 E7 – efficiency of intervention[31], efficiency[10,19,22,23,44],
opportunity costs[10], opportunity costs to the population/society[16],
best within available resources[38], interdependencies[50]
E8: Resources: 5 terms,
6 times
 E8 – resources[17,51], variation in rate of use[45], available
resources[13], resources implications[50], volume of activity[13]
E9: Insurance premiums:
1 term, 1 time
 E9 – impact on health insurance premiums[9]
F-Quality and
uncertainty of evidence
Number of criteria: 6 Number of terms: 34
F1: Evidence available:
7 terms, 9 times
 F1 – evidence[22,42,45], proof[22], scientific evidence[47],
current level of knowledge[17], time of assessment in technology
development[35], timelines of review[45], therapy mechanism
of action[23]
F2: Strength of evidence:
14 terms, 20 times
 F2 – strength of evidence[16,44], quality of evidence[47], quality of
data and past decisions[47], quality of data[22], quality[26], validity of
evidence[10,19], related degree of knowledge certainty[23],
certainty[48], consistency[19,22,44], consistent[38], completeness and
consistency of reporting evidence[10], openness[26,44], selection of
studies[35,40], precision of treatment effect[22]
F3: Relevance of evidence:
5 terms, 8 times
 F3 – relevance of evidence[10,19], representativeness of users
(studies vs. real world)[35,40], level of generalization[35,40], effectiveness
in real practice[22], evidence of effectiveness[44]
F4: Evidence characteristics:
5 terms, 7 times
 F4 – normative characteristics of study[35,40], choice of
endpoints[35,40], clinical trial data[47], multiple randomized trials or
meta-analysis/single randomized trial of reasonable size/small
randomized trial[42], phase II[53]
F5: Research ethics:
2 terms, 4 times
 F5 – research ethics[35,40], informed consent[26,40]
F6: Evidence requirements:
1 term, 1 time
 F6 – adherence to requirement of decision making body[10]
G-Implementation
complexity of
intervention
Number of criteria: 9 Number of terms: 57
G1: Legislation: 6 terms,
6 times
 G1 – legal arrangements[40], legislative issues[22], medical
liability[40], human rights legislation[23], legal implications[45],
conformity of programs[22]
G2: Organizational requirements
and capacity to implement:
15 terms, 17 times
 G2 – system requirements[25], physical environment [44],
environment[22,26], system capacity[10], local capacity[17], ability to
implement[38], implementation[22], organization’s structure[51],
organizational burden[49], logistics[36], process[28],
well-organized[38], organizational feasibility[22,25], feasibility
of delivery[16], deliverability[48]
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Table 2 Classification of terms reported in the literature (Continued)
G3: Skills: 6 terms, 6 times  G3 – knowledge and skills[51], nature of staff[51], clinical
education and training[44], human resources availability[17],
recruitment and retention of staff[44], attracting/retaining scarce
clinical staff[44]
G4: Flexibility of
implementation:
7 terms, 8 times
 G4 – flexibility[51], reversibility[51], trialiability[51], revisability[51],
ability to evaluate[22], provision for revision/appeals[38],
engagement[26,48]
G5: Characteristics of
intervention: 6 terms,
8 times
 G5 – characteristics of intervention[22], complexity of the
intervention[51], components of technology[35], autonomy of the
intervention[38], autonomy[17,26,46], convenience[42]
G6: Appropriate use:
3 terms, 3 times
 G6 – appropriate use of intervention[10], appropriateness[44],
appropriate setting/level of service[43]
G7: Barriers and acceptability:
3 terms, 4 times
 G7 – acceptability[22,48], responsiveness[44], controversial
nature of proposed technology[45]
G8: Integration and system
efficiencies: 9 terms, 9 times
 G8 – system integration (best use of elements of healthcare
system)[34], integration into local community[44], ease of
integration[22], impact on other services[40], links to other
services[44], compatibility[22], reduction of the monitoring[33],
reduction of waiting list size[33], impact[22]
G9: Sustainability: 2 terms,
4 times
 G9 – sustainability[23,24,26], longevity[19]
H-Priorities,
fairness and ethics
Number of criteria: 7 Number of terms: 55
H1 Population priorities:
5 terms, 5 times
 H1 – perspective and current priority[13], target and
priority-setting[14], known priorities[44], population priority[10],
coverage of selected conditions[13]
H2 : Access: 10 terms, 17 times  H2 – population access[10], access[19,27,47,49], equity
of access improvement[13], access to care easier[31,33,34],
distribution and access to healthcare[35,40], accessibility[22,44], equity
of access[44], access to health system[22], geographical equity[43],
timeliness of access[43]
H3 : Vulnerable and needy
population: 9 terms, 11 times
 H3 – vulnerable population[37,38], potential victims[40], particular
social groups with high risk and/or increased vulnerability[23],
compassion for the vulnerable[19], particularly needy/vulnerable
groups[44], age of targeted group[13,30], maternal mortality[13],
quality of maternity care services[13], population equity[43]
H4: Equity, fairness and
justice: 12 terms, 32 times
 H4 – equity[8,13,14,19,22,25,27,40,44,46,48], fairness[10,14,40,44,47],
health equity[23,26], equality[19,26,38], distributive justice[23,25], formal
justice[23], social justice[23], justice[26,46], social injustice[40], addressing
health status inequalities at a population level[44], human integrity and
dignity[35,40], basic human rights[35]
H5 : Utility: 2 terms, 3 times  H5 – utility[10,26], utilitarism[25]
H6: Solidarity: 6 terms, 8 times  H6 – solidarity[19,25,26], collectivism[26], mutuality[26], reciprocal
trust[40], diversity[26], cohesion[26]
H7: Ethics and moral
aspects: 11 terms, 14 times
 H7 – ethics[14,22], ethical values[22], values[22], values and
beliefs[51], consistency with societal values[22], ethical implications[45],
moral obligation to implement a technology[35,40], rule of rescue[25],
priority to basic and necessary care[38], moral consequence of
HTA[35,40], moral challenges related to certain components
of HTA[35]
I-Overall context Number of criteria: 11 Number of terms: 83
I1: Mission and mandate
of health system: 13 terms,
19 times
 I1 – goals of healthcare[52,53], goals[21], beneficence[28], non-
maleficience and justice[28], beneficence/non-maleficience[17,26,53],
strategic fit[9,23], medical and social worth[45], relevance[22], present
social consensus,[17,49] consensus regarding public funding of a
therapy[17,53], government mandate[17], national standards[24],
healthcare context positioning[23]
I2: Overall priorities:
6 terms, 6 times
 I2 – national priorities[45], national or board priority[14], local and
national priorities[8], international priorities[45], alignment with external
directives[9], strategic direction[43]
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need (D2, 16 citations). Among these 10 most frequently
cited criteria, three criteria were from the category
“A - Health benefits and outcomes of intervention”,
highlighting the importance of this consideration in
decisionmaking. The other most frequently cited criteria
were from seven categories of criteria, indicating that
the classification system captured critical criteria in dis-
tinct categories.
At the category level (Figure 4), the number of citations
was the highest for the category of criteria “Overall con-
text” (106 citations); followed by “Priorities, fairness and
ethics” (90 citations); “Health outcomes and benefits of
intervention” (81 citations); “Economic impact of inter-
vention” (75 citations); “Implementation complexity of
intervention” (65 citations); “Quality and uncertainty of
evidence” (49 citations); “Impact of disease targeted” (40
citations); “Therapeutic context of intervention” (37 cita-
tions); and “Type of service provided” (18 citations).
Discussion
This literature review revealed a burgeoning number of
studies examining healthcare decision criteria and
criteria-based decisionmaking tools, especially over the
last five years. Criteria were identified from studies per-
formed in several regions of the world involving deci-
sionmakers at micro, meso and macro levels of decision
and from studies reporting on multicriteria tools. In-
creasingly, the healthcare community is aware that be-
yond cost-effectiveness, other criteria must be taken
explicitly into account for transparent and consistent
healthcare decisionmaking and priority-setting [54-56].
Indeed, elucidating decision criteria and how they are
considered are key to establishing accountability and
reasonableness of decisions. This is necessary to fulfill
the relevance condition of the accountability for reason-
ableness (A4R) framework of Daniels and Sabin [6],
which states that “Decisions should be made on the basis
of reasons (i.e. evidence, principles, values, arguments)
Table 2 Classification of terms reported in the literature (Continued)
I3: Financial constraints:
8 terms, 13 times
 I3 – budget constraints[13,33,45], cost-containment[42,49], budget
level[13,19,45], social economical context[16], limited provincial health
resources[17], budget implementation challenges[17], economic
feasibility[37], reliance of other services/sectors(on investment)[14]
I4: Incentives:
4 terms, 5 times
 I4 – financial incentives[28,45], organizational support[16], donor
involvement[31], incentives for compliance[20]
I5: Political aspects:
5 terms, 7 times
 I5 – political pressure[13,19,45], political components[52], politically
and legally defensible decisions[42], politics[37], political impact[37]
I6: Historical aspects:
3 terms, 3 times
 I6 – historical components[52], past experiences[16], historical
budgets[19]
I7: Cultural aspects:
7 terms, 10 times
 I7 – culture and religious convictions[19,28,47], stigma[28],
compatibility with values[16], challenge of social and values
arrangements[28,47], conception of certain persons or disease[47],
psychosocial implications[34], public preference[14]
I8: Innovation:
3 terms, 3 times
 I8 – perceived benefits of change[16], innovativeness[37],
generation or application of knowledge[43]
I9: Partnership and
leadership: 8 terms,
9 times
 I9 – partnership and networking[16], partnerships[9], maintaining
relationship[42], leadership[16], community development[53], academic
commitments: research and education[9,23], partnership and
collaboration across organizations[43], contribution to position
as a learning organization[43]
I10: Citizen involvement:
3 terms, 3 times
 I10 – citizenship[53], ownership[53], enabling health literacy
(empowerment)[53]
I11: Stakeholders
interests and pressures:
23 terms, 28 times
 I11-stakeholders pressure[52], advocacy[16,45], pressure from
physician and patients groups and past decisions[32], clinical expert
opinions[37], patient representative group opinions[37], power
relations among stakeholders[28], user of the technology interests[47],
challenge the relationship between patient and physician[47],
professional prestige[28,47], clinicians excitement and decisions in
other hospitals[32], public reaction and public accountability[28], HTA’s
producer interest[28,47], company activities[32], researchers ethics
interests[28,47], third party agents involved[47], recommendations
made by other countries[13], status in other jurisdictions[49], current
status of public funding in other jurisdictions[17], drugs used in other
hospitals[32], expressed demand[14,37], patient demand[32],
expected level of interest (patient and medical)[34], entitlement[28]
This table is reporting all the terms (338) extracted from the selected articles and tabulates them using the classification system developed for this study, which is
based on a hierarchical approach clustering 58 criteria into 9 categories.
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that ‘fair-minded’ stakeholders can agree are relevant
under the circumstances”.
This analysis revealed a predominance of normative
criteria, that is, answering the question “what should be
done?” This highlights the importance of considering the
actual worth or value of healthcare interventions rather
than just feasibility criteria, (“What can be done?”). Of
the ten most frequently cited criteria, eight were norma-
tive (equity and fairness, efficacy, cost-effectiveness,
strength of evidence, safety, mission and mandate of
healthcare system, need, patient-reported outcomes) and
two were feasibility criteria (stakeholder pressures and
interests, organizational requirements and capacity).
This is aligned with a review of studies on decision
Figure 3 Classification system and number of citations for each criterion.
106
90
65
49
75
37
40
18
81
0 20 40 60 80 100
I Overall context
H Priorities ,fairness and ethics
G Implementation complexity of intervention
F Quality and uncertainty of evidence
D Therapeutic context of intervention
C Impact of disease targeted
B Type of service provided
A Health outcomes and benefits of intervention
E Economic impact of intervention
Figure 4 Number of citations for each category of criteria of the classification system.
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criteria in developing countries [13], and points to the
need to include both normative and feasibility criteria in
decision and prioritization tools to fully reflect and sup-
port the decisionmaking process.
The criterion “equity and fairness” was the most fre-
quently reported. This may reflect that equity is a guiding
principle in defining the values on which decisions are
based. Equity is difficult to operationalize in decisionmak-
ing and priority-setting processes in a pragmatic manner.
It is a complex ethical concept that eludes precise defin-
ition and is synonymous with social justice and fairness
[57]. It is referred to as “a fair chance for all,”[23] “equality
of access to healthcare resources on the basis of need,”[8]
“absence of systematic disparities in health (or in the
major social determinants of health) between groups with
different levels of underlying social advantage/disadvan-
tage”[58]. The WHO advocates concepts of “horizontal
equity, providing healthcare to all those who have the
same health need, and vertical equity, providing preferen-
tially to those with the greatest need” [57]. The difficulty
of considering equity in a pragmatic manner points to the
need to include it systematically as operationalizable cri-
teria in the decision process. If not systematic, it is less
likely that decisions will be equitable. Decisions are gener-
ally fairest when standards are predetermined, explicit and
consistently applied [59]. Equity is embedded in consider-
ation of disease severity in prioritization of healthcare
interventions. Decisionmakers generally attach more value
to interventions for severe disease than for mild disease.
This is also translated in the worst-off principle, which
relates to an independent concern for severity; “the worse
off an individual would be without an intervention, the
more highly society tends to value that intervention” [60].
Systematic consideration of criteria defined on the basis of
population priorities identified by decisionmakers (e.g.,
more value for interventions targeted to vulnerable popu-
lations such as children, the elderly, those in remote areas)
is another pragmatic way to incorporate equity into deci-
sionmaking. Integration of ethical considerations in opera-
tionalizable criteria was developed for the comprehensive
multicriteria framework EVIDEM [61]. Ethical issues are
an integral part of the EUnetHTA core model to ensure
their explicit considerations [46], and several frameworks
focusing on equity [62] and ethical issues [63] have re-
cently emerged.
Efficacy/effectiveness was the second most frequently
reported criterion; as Hawkes discussed recently, “gov-
ernments are wrestling with the issues of efficacy and
fairness in healthcare delivery” [64]. While efficacy mea-
sures the effect of an intervention treatment under
controlled conditions (such as during clinical trials), ef-
fectiveness provides critical information on outcomes
actually achieved by an intervention in real life settings.
Efficacy and effectiveness are fundamental criteria
considered at the regulatory (e.g., FDA, EMA) and reim-
bursement levels for medicines in many jurisdictions
[65-67]. Because decisions concerning interventions at
policy, clinical and patient level are made with reference
to a given context of care (usually standard of care), im-
provement over existing care rather than absolute effi-
cacy or effectiveness provides the most informative
evidence [10]. Indeed, decisions about usefulness of in-
terventions are usually based on relative advantage
compared to existing approaches [15]. Comparative ef-
fectiveness, “the comparative assessment of interven-
tions in routine practice settings” [68] is meant to help
answer the question “does it work in my context?” and
is demand-driven research aimed directly at decision-
maker needs [69]. For new interventions, however, ef-
fectiveness data is usually not available and decisions
are often made on the basis of efficacy data, with the
uncertainty inherent in innovation [67]. Evidence-based
decisionmaking relies on actual benefits derived from
an intervention so mechanisms (such as defining sub-
criteria) outlining specifically the most relevant out-
comes of efficacy/effectiveness in real life are critical
to ensure that the dimensions of efficacy/effectiveness
are fully captured and communicated.
The third most commonly reported criterion refers to
stakeholder interests and pressures. Macro-level deci-
sions are influenced by public pressure and advocacy
[13,15,38] and the demand for a new program is a
powerful argument for decisionmakers at the political
level [70]. In a study exploring the basis for immuniza-
tion recommendations, while vaccine safety was reported
as important or very important in making immunization
recommendations by all countries regardless of eco-
nomic status, low and lower middle income countries
were significantly more likely than developed countries
to report that public pressure was an important factor
[9]. Because pressures from groups of stakeholders are
often part of the context [10], being aware of pressures
and interests at stake and how they may affect decision-
making and implementation is important and should be
explicitly tackled using a framework that encourage sys-
tematic consideration of their potential implications
when making healthcare decisions.
Cost-effectiveness was the fourth most commonly
reported criterion. Cost-effectiveness is frequently used
in healthcare decisionmaking [65,71] but its usefulness is
the subject of debate [54,56]. A review of 36 empirical
studies reported that the influence of cost-effectiveness
was moderate at micro, meso and macro levels of deci-
sion [55]. Designed to incorporate several criteria of deci-
sion (e.g., cost, efficacy/effectiveness, safety, quality of
life) into an aggregated ratio allowing comparisons of
interventions, it fails to include important criteria such
as equity and the severity of the targeted condition [59].
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In addition, cost-effectiveness thresholds are commonly
mistaken for affordability thresholds [59]. Beyond cost-
effectiveness ratios, health economic studies generate
data that are necessary to evaluate healthcare interven-
tions (e.g., resource utilization and cost consequences of
a new intervention compared to existing care).
This study also revealed that strength of evidence is an
important aspect in decisionmaking, highlighting the in-
fluence of evidence-based medicine. Evidence is usually
sought to demonstrate effectiveness (“it works”), show
the need for policy action (“it solves a problem”), guide
effective implementation (“it can be done”), and clarify
cost-effectiveness (“it provides value for money”) [15].
The quality of evidence that decisionmakers use can
only be determined when several concepts are consid-
ered, such as scientific validity, completeness and rele-
vance to the decisionmaking context [18]. The strength
of evidence builds with time as interventions are used in
real life and initial decisions made in a context of uncer-
tainty (e.g., randomized clinical trial data in limited
populations) may be revisited as evidence accumulates.
A common question is how much evidence is enough to
make an evidence-based decision [59]. Beyond scientific
evidence, decisionmaking also relies on colloquial evi-
dence [72]. Consideration of strength and quality of the
different types of evidence remain an important part of
the appraisal of interventions.
Safety, a critical element of policy and clinical practice,
was the sixth most cited criterion. Safety refers to the fre-
quency and severity of adverse events or complications
arising as a result of using the new technology compared
to an alternative [22]. Efficacy and safety are the main
criteria in the initial evaluation of a new intervention
[70]. And the risk-to-benefit equation is a critical compo-
nent of clinical and regulatory decisionmaking [67].
A number of other criteria were identified high-
lighting the complexity of healthcare decisionmaking
and the need to support this process with tools to en-
sure consistency, transparency and accountability for
reasonableness. An important milestone towards that
goal would be to harmonize terminology. Indeed, a
large variety of terminology was found in the litera-
ture during analysis and classification of criteria. Al-
though a systematic approach was used to classify
terms into criteria and overarching categories using
the principles of MCDA, such analyses are limited by
the subjective interpretation of terms reported by
authors. For example, the terms reported in published
studies such as “side effects,” “unintended conse-
quences,” “risks,” “harm,” or “adverse effects” were all
grouped under the criterion “Safety.” These variations
of terminology underline the difficulty of harmonizing
the decisionmaking processes, as several authors have
noted [10,11]. It calls for well-defined criteria to avoid
confusion and ensure sound application of multicri-
teria approaches to decisionmaking [11,73].
Although this analysis was limited to published studies,
an extensive analysis of decisionmaking processes from jur-
isdictions around the world for coverage of healthcare
interventions was performed to define the criteria of the
EVIDEM framework, which are included in this analysis
[10,18]. In addition, the large number of terms retrieved
covers criteria currently used in more than 25 decision-
making processes for coverage of medicines [65].
Conclusion
This study highlights the importance of considering both
normative and feasibility criteria for decisionmaking and
priority setting of healthcare interventions. By providing a
comprehensive classification of decisionmaking criteria,
this analysis can promote reflection on the value of har-
monizing terminology in this field. It can also serve as a re-
source when considering which criteria to include in
sound multicriteria approaches (i.e., fulfilling principles of
completeness, lack of redundancy, mutual independence,
operationalizability and clustering). This analysis is also
used as a foundation for the development of an inter-
national survey on criteria expected to further expand our
knowledge of real-life decisionmaking and advance multi-
criteria approaches.
Such approaches have the potential to integrate and fa-
cilitate pragmatic operationalization of a large range of
considerations, including ethical considerations, in a
transparent and consistent process. They could provide a
common metric for curative and preventive interventions
to clearly define best health improvements within resource
available, as recently advocated by Volp and colleagues
[74]. They may also provide a road map to develop more
participative decisionmaking processes by “better combin-
ing of many elements” proposed by Culyer [75].
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